Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer


Journal of Thoracic Oncology (2017), doi: 10.1016/j.jtho.2017.10.011.
韩国三星医学中心回顾性分析,评估PD-1/PD-L1抑制剂是否会影响SCAI(salvage chemotherapy administered after immunotherapy,免疫治疗后的挽救性化疗)的疗效,将其与LCBI(last chemotherapy administered before immunotherapy,免疫治疗前的这线化疗)对比。共纳入73例分析,其中有10例接受了一线PD-1/PD-L1抑制剂治疗,63例LCBI 缓解数据可得。73例SCAI , 39例 (53.4%)缓解,而LCBI 缓解率为34.9% (22/63),p=0.03。根据含铂双药化疗、非含铂单药化疗进行分层,含铂双药化疗的缓解率在SCAI和LCBI分别为66.7%(16/24)和39.5%(17/43),p=0.03;非含铂单药化疗方案分别为 46.9% (23/49)和25.0%(5/20),p=0.09。结论:SCAI缓解率显著高于LCBI。这些数据提示抗PD-1/PD-L1抑制剂可能改善肿瘤对后续化疗的敏感性。